Back to top
more

Amgen (AMGN)

(Delayed Data from NSDQ)

$319.66 USD

319.66
1,467,828

+2.18 (0.69%)

Updated Oct 4, 2024 04:00 PM ET

After-Market: $319.25 -0.41 (-0.13%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 33% (83 out of 252)

Industry: Medical - Biomedical and Genetics

Better trading starts here.

Zacks News

Sweta Killa headshot

Dow Jones ETF Avoids Bear Market: 4 Stocks in Green

Both the S&P 500 and the tech-heavy Nasdaq Index are in bear market while the Dow Jones in the only of the three main indexes not to have bear market status.

AstraZeneca's (AZN) Asthma Drug Tezepelumab Gets Nod in Europe

AstraZeneca's (AZN) Tezspire is the only biologic medicine approved in Europe to treat severe asthma with no phenotype limitation and irrespective of biomarker levels.

Amgen (AMGN) Stock Moves -1.43%: What You Should Know

Amgen (AMGN) closed at $224.46 in the latest trading session, marking a -1.43% move from the prior day.

Novartis (NVS) Unit Posts Positive Results on Prolia Biosimilar

Novartis (NVS) generic unit Sandoz announces that ROSALIA study for its proposed biosimilar of Prolia (denosumab) meets primary endpoints.

Amgen (AMGN) Stock Moves -0.2%: What You Should Know

Amgen (AMGN) closed the most recent trading day at $227.66, moving -0.2% from the previous trading session.

Bristol Myers (BMY) Gets FDA Approval for Psoriasis Candidate

Bristol Myers (BMY) secures an FDA nod for Sotyktu to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.

Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?

Smart Beta ETF report for IBB

Amgen (AMGN) Gains But Lags Market: What You Should Know

Amgen (AMGN) closed at $247.69 in the latest trading session, marking a +0.91% move from the prior day.

The Zacks Analyst Blog Highlights: T-Mobile US, NextEra Energy, Amgen, 3M and Itau Unibanco Holding

T-Mobile US, NextEra Energy, Amgen, 3M and Itau Unibanco Holding are part of The Zacks top Analyst Blog .

Mark Vickery headshot

Top Stock Reports for T-Mobile, NextEra Energy & Amgen

Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc. (TMUS), NextEra Energy, Inc. (NEE) and Amgen Inc. (AMGN).

Should You Invest in the iShares Biotechnology ETF (IBB)?

Sector ETF report for IBB

Amgen (AMGN) Gains But Lags Market: What You Should Know

Amgen (AMGN) closed the most recent trading day at $244.79, moving +1.06% from the previous trading session.

Abhinab Dasgupta headshot

Take the Zacks Approach to Beat the Market: Walmart (WMT), Ulta Beauty (ULTA), UniCredit (UNCFF) in Focus

Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our accomplishments from last week.

3 Top-Ranked Dividend Stocks: A Smarter Way to Boost Your Retirement Income

The traditional ways to plan for your retirement may mean income can no longer cover expenses post-employment. But what if there was another option that could provide a steady, reliable source of income in your nest egg years?

Amgen's (AMGN) Lumakras Meets Goal in New Lung Cancer Study

Amgen's (AMGN) phase III CodeBreaK 200 study evaluating once-daily oral, Lumakras, for treating KRAS G12C-mutated non-small cell lung cancer meets its primary endpoint.

Aerie (AERI) Rallies 205.6% in the Past Three Months: Here's Why

Aerie (AERI) shares have skyrocketed in the past three months after the company announced its definitive agreement with Alcon, wherein the latter will acquire the former for $770 million.

Amgen (AMGN) Outperforms Industry Year to Date: What's Next?

Amgen's (AMGN) key drugs like Prolia, Repatha and Xgeva are driving sales. Amgen is also rapidly advancing its robust pipeline of early and late-stage assets.

    Amgen (AMGN) Posts Positive Data from Soliris' Biosimilar Study

    Amgen's (AMGN) phase III study evaluating ABP 959, a biosimilar candidate to Soliris for treating paroxysmal nocturnal hemoglobinuria, meets the primary endpoint.

    Sanghamitra Saha headshot

    How Are Biotech ETFs Reacting to Q2 Earnings Releases?

    he Biotech sector has been in a sweet spot for quite some time now. Plus, earnings releases have also come in mostly upbeat.

      The Zacks Analyst Blog Highlights Coca-Cola, Oracle, Morgan Stanley, Amgen and TotalEnergies

      Coca-Cola, Oracle, Morgan Stanley, Amgen and TotalEnergies are included in this Analyst Blog.

      Sheraz Mian headshot

      Retail Scorecard and Analyst Reports for Coca-Cola, Oracle & Morgan Stanley

      Today's Research Daily features update on the Q2 earnings season and new research reports on The Coca-Cola Company (KO), Oracle (ORCL) and Morgan Stanley (MS).

      Amgen (AMGN) is a Top-Ranked Value Stock: Should You Buy?

      Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

      The Zacks Analyst Blog Highlights Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals

      Amgen, ChemoCentryx, Mersana Therapeutics, GSK and Vertex Pharmaceuticals are part of the Zacks top Analyst Blog.

      Biotech Stock Roundup: AMGN's Q2 Earnings, CCXI Acquisition & More Updates

      Earnings updates from Amgen (AMGN) and its ChemoCentryx (CCXI) acquisition are a few key highlights from the biotech sector during the past week.